BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35496814)

  • 1. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic.
    Kamath C; Brenner EJ
    Curr Res Pharmacol Drug Discov; 2022; 3():100101. PubMed ID: 35496814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.
    Agrawal M; Zhang X; Brenner EJ; Ungaro RC; Kappelman MD; Colombel JF
    J Crohns Colitis; 2021 Nov; 15(11):1877-1884. PubMed ID: 33884425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Lee MH; Li HJ; Wasuwanich P; Kim SE; Kim JY; Jeong GH; Park S; Yang JW; Kim MS; Yon DK; Lee SW; Koyanagi A; Jacob L; Kim EY; Cheon JH; Shin JI; Smith L
    Rev Med Virol; 2023 Mar; 33(2):e2414. PubMed ID: 36504172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine therapy in inflammatory bowel disease in the pandemic era: Safe or unsafe?
    Perdalkar S; Basthi Mohan P; Musunuri B; Rajpurohit S; Shetty S; Bhat K; Pai CG
    Int Immunopharmacol; 2023 Mar; 116():109597. PubMed ID: 36702073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.
    Agrawal M; Brenner EJ; Zhang X; Colombel JF; Kappelman MD; Ungaro RC; ; Gearry RB; Kalpan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE
    J Crohns Colitis; 2021 May; 15(5):860-863. PubMed ID: 33232456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
    Alrashed F; Battat R; Abdullah I; Charabaty A; Shehab M
    BMJ Open Gastroenterol; 2021 Oct; 8(1):. PubMed ID: 34725056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease in the COVID-19 era.
    Kim KO; Jang BI
    Intest Res; 2022 Jan; 20(1):3-10. PubMed ID: 33525860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of biologics in inflammatory bowel disease patients with COVID-19.
    Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
    Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients.
    Ricciuto A; Lamb CA; Benchimol EI; Walker GJ; Kennedy NA; Kuenzig ME; Kaplan GG; Kappelman MD; Ungaro RC; Colombel JF; Brenner EJ; Agrawal M; Reinisch W; Griffiths AM; Sebastian S
    J Crohns Colitis; 2022 May; 16(4):591-600. PubMed ID: 34570886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned.
    Gajendran M; Perisetti A; Aziz M; Raghavapuram S; Bansal P; Tharian B; Goyal H
    Ann Gastroenterol; 2020; 33(6):591-602. PubMed ID: 33162736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.
    Allez M; Fleshner P; Gearry R; Lakatos PL; Rubin DT
    J Crohns Colitis; 2020 Oct; 14(14 Suppl 3):S774-S779. PubMed ID: 32722757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of IBD medications on COVID-19 outcomes: results from an international registry.
    Ungaro RC; Brenner EJ; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gut; 2021 Apr; 70(4):725-732. PubMed ID: 33082265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R
    Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease.
    Benchimol EI; Carroll MW; Geist R; Griffiths AM; Huang JG; Mack DR; Bernstein CN; Bitton A; Jones JL; Kaplan GG; Kuenzig ME; Lee K; Mukhtar MS; Murthy SK; Tandon P; Targownik LE; Windsor JW; Seow CH
    J Can Assoc Gastroenterol; 2021 Dec; 4(Suppl 2):S27-S33. PubMed ID: 34755036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.
    Alrashed F; Alasfour H; Shehab M
    JGH Open; 2022 Apr; 6(4):241-250. PubMed ID: 35475207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing IBD in the COVID-19 era.
    Scalzo N; Ungaro RC
    Therap Adv Gastroenterol; 2023; 16():17562848231176450. PubMed ID: 37337593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience.
    Richter V; Bermont A; Cohen DL; Broide E; Shirin H
    Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):267-273. PubMed ID: 34191758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
    Troncone E; Marafini I; Del Vecchio Blanco G; Di Grazia A; Monteleone G
    Clin Exp Gastroenterol; 2020; 13():131-139. PubMed ID: 32440190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.